Table 1 Clinical trials of PROTACs compounds, disease or tumor for which they are being tested, and clinical phase
From: Clinical considerations for the design of PROTACs in cancer
NCT | Compound (Target) | Conditions | Phase |
|---|---|---|---|
NCT03888612 | ARV-110 (AR) | Prostate cancer metastatic | I/II |
NCT04072952 | ARV-471 (ER) | Breast cancer | I/II |
NCT05067140 | ARV-766 (AR) | Prostate cancer metastatic | I |
NCT04428788 | CC-94676 (AR) | Prostatic neoplasms | I |
NCT04886622 | DT2216 (BCL-xL) | Solid tumor/Hematologic malignancy | I |
NCT04772885 | KT-474 (IRAK4) | Healthy volunteer/atopic dermatitis/hidradenitis suppurativa | I |
NCT04830137 | NX-2127 (BTK) | Hematologic malignancy | I |
NCT03891953 | DKY709 (IKZF2) | Non-small-cell lung carcinoma/Melanoma/Nasopharyngeal carcinoma/Colorectal cancer/TNBC | I |